Daniel Massey

University of Colorado Boulder

H-index: 42

North America-United States

About Daniel Massey

Daniel Massey, With an exceptional h-index of 42 and a recent h-index of 17 (since 2020), a distinguished researcher at University of Colorado Boulder, specializes in the field of Cybersecurity, networks, CPS.

His recent articles reflect a diverse array of research interests and contributions to the field:

XENERA-1: A randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone …

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

of print.

181TiP Xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 …

DroneScale: drone load estimation via remote passive RF sensing

Daniel Massey Information

University	University of Colorado Boulder
Position	___
Citations(all)	11665
Citations(since 2020)	2895
Cited By	9379
hIndex(all)	42
hIndex(since 2020)	17
i10Index(all)	82
i10Index(since 2020)	25
Email	Access Email
University Profile Page	University of Colorado Boulder
Google Scholar	View Google Scholar Profile

Daniel Massey Skills & Research Interests

Cybersecurity

networks

CPS

Top articles of Daniel Massey

Title	Journal	Author(s)	Publication Date
XENERA-1: A randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone …	Breast Cancer Research	Peter Schmid Javier Cortes Ana Joaquim Noelia Martínez Jañez Serafín Morales ...	2023/6/12
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations	Journal of Clinical Oncology	Lecia V Sequist James Chih-Hsin Yang Nobuyuki Yamamoto Kenneth O'Byrne Vera Hirsh ...	2023/6/1
of print.	Biochemistry	AH Pang KD Green A Punetha N Thamban Chandrika KC Howard ...	2023/1/19
181TiP Xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 …	Annals of Oncology	P Schmid HS Rugo J Cortés P Blum K Crossley ...	2020/5/1
DroneScale: drone load estimation via remote passive RF sensing		Phuc Nguyen Vimal Kakaraparthi Nam Bui Nikshep Umamahesh Nhat Pham ...	2020/11/16